IPHA innate-pharma.com Price Chart

The development of Innate Pharma S.A. (IPHA) relies on progress in immuno-oncology and strong ties with pharmaceutical behemoths, while access to investment and development milestone bonuses constitute 1.58. The French business faces risks due to diverging Western regulations and potential disruptions in biomaterial supplies. The market price confirmed by this chart is supplemented by data on the implementation of automated systems for accelerated molecule selection.

IPHA - Innate Pharma S.A Price Performance Chart over the range 07/04/2022 - 11/12/2026

Summary analytical data breakdowns for Innate Pharma SA (IPHA)

- stock quotes and analyst forecast:

Stock Price Innate Pharma S.A.|IPHA - Analyst Median Target

- market capitalization data:

Market Value Innate Pharma SA|IPHA - Full Business Value

- balance sheet equity data:

Book Value per Share Innate Pharma|IPHA - Accounting Value of Company|Market Capitalization to Book Value Ratio innate-pharma.com|IPHA - Company Total Assets

- company total debt and liquidity indicators:

- earnings and market ratios statistics:

IPHA - Company Net Income|Expected Profit Innate Pharma S.A.|IPHA - Market Cap to Earnings|Forward P/E Multiple Innate Pharma|IPHA - Price to Net Income Growth Ratio|Enterprise Value to EBITDA Ratio Innate Pharma SA|IPHA - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Innate Pharma|IPHA - Earnings per share for the trailing year|Quarterly EPS earnings growth innate-pharma.com|IPHA - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Innate Pharma S.A.

Summary company analytics:Innate Pharma S.A.

Signature product of Innate Pharma, S.A.

To select high-quality assets, an investor must compare the fundamental value of a business with its current market valuation. The price records the value of the session's last trade, reflecting aggregate market demand, which is critical for Innate Pharma S.A. (IPHA) when assessing risks of regulatory fragmentation and logistical disruptions that impact market price fluctuations.

Competitors of Innate Pharma S.A.